Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04478708 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
A Phase 1 study of Obesity, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 3
- Study locations
NCT04478708: Completed Phase 1 study of Obesity, sponsored by Amgen.
NCT04478708 is a Phase 1 study of Obesity that has completed, run by Amgen. The registered enrollment target is 110 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04478708, a Phase 1 study of Obesity, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
Primary Outcome
A TEAE was defined as any adverse event (AE) which started on or after the first dose of AMG 133. Clinically significant changes in laboratory safety tests, vital signs and 12-lead electrocardiograms (ECGs) were included as AEs.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL maridebart cafraglutide
Study Locations (3)
California
- Anaheim Clinical Trials - Anaheim
- Orange County Research Center - Tustin
Florida
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 1 |
What the finished NCT04478708 record still lists
NCT04478708 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04478708 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT04478708 about?
NCT04478708 is a clinical study titled "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity". The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
What is the current status of trial NCT04478708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2020-08-07. Estimated completion is 2022-11-18.
What conditions does trial NCT04478708 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT04478708?
The interventions under investigation include: Placebo (DRUG), maridebart cafraglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT04478708?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04478708 being conducted?
This trial has 3 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04478708's enrollment target sits among peer trials
110 458th of 1053 higher than 594 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI